A Multicenter, Randomized, Double-blind, Positive-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of WXSH0102 Tablets in the Treatment of Vulvovaginal Candidiasis (VVC)
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs WXSH-0102 (Primary) ; Fluconazole
- Indications Vulvovaginal candidiasis
- Focus Therapeutic Use
- Sponsors Cisen Pharmaceutical
- 20 Jan 2025 New trial record